Galanthamine and physostigmine are clinically used cholinomimetics that both inhibit acetylcholinesterase and also interact directly with and potentiate nAChRs. As with most nAChR-positive allosteric modulators, the location and number of their binding site(s) within nAChRs are unknown. In this study, we use the intrinsic photoreactivities of [ 
Introduction
The development of drugs that enhance brain nAChR function represents an important approach for the treatment of many cognitive and neurodegenerative disorders (Faghih et al., 2008; Taly et al., 2009; Williams et al., 2011) . The ability of physostigmine and galanthamine to improve cognitive functions in a subset of Alzheimer's patients (van Dyck et al., 2000; Cummings, 2004) was originally attributed to their inhibition of acetylcholinesterase, but it is now recognized that direct interactions with brain nAChRs may also contribute to their efficacy (Maelicke and Albuquerque, 2000; Wilkinson et al., 2004; Geerts et al., 2005) . Physostigmine and galanthamine potentiate agonist-induced responses and, in the absence of agonist, directly activate nAChRs by binding to site(s) apparently distinct from the transmitter binding sites (Pereira et al., , 1994 Samochocki et al., 2003; Akk and Steinbach, 2005; Militante et al., 2008) . Since the introduction of physostigmine, other structurally unrelated drugs have been identified as nAChR-positive allosteric modulators, which suggests the presence of more than one class of nAChR positive allosteric modulator binding sites (Bertrand and Gopalakrishnan, 2007; Arias, 2010; Williams et al., 2011) . Mutational analyses provided evidence for binding sites in the ␣7 nAChR transmembrane domain for PNU-120596 (Young et al., 2008; daCosta et al., 2011) and in the extracellular domain for galanthamine at the "canonical" subunit interfaces (those containing the transmitter binding sites) (Ludwig et al., 2010) , whereas mutations in the ␣3␤2 nAChR predicted a binding site for morantel at "noncanonical" subunit interfaces (Seo et al., 2009) .
In this report, we use the intrinsic photoreactivities of physostigmine and galanthamine and protein microsequencing to identify their binding site(s) in the muscle-type Torpedo nAChR. Photoaffinity labeling has been used to identify amino acids in the Torpedo nAChR transmitter binding sites (Mourot et al., 2006) and in binding sites for positive and negative allosteric modulators . Unlike mutational analyses, photoaffinity labeling allows direct identification of residues in a drug binding site (Vodovozova, 2007) and therefore distinguishes amino acids that contribute to a positive allosteric modulator binding site from those involved in allosteric modulation of gating.
The Torpedo nAChR is comprised of five homologous subunits (␣ 2 ␤␥␦) assembled around a central axis that is perpendicular to the membrane bilayer. The transmembrane domain consists of each subunit's 4 transmembrane helices (M1-M4), with the five M2s lining the ion channel (Unwin, 2005) . The extracellular domain of each subunit consists of a 10-strand ␤-sandwich with transmitter binding sites at the ␣-␥ and ␣-␦ subunit interfaces. The ␣ subunit provides the core aromatic residues of the binding site principal surface, whereas amino acids from the ␥ or ␦ subunit on a ␤ sheet form a rigid, complementary surface at the entry to the aromatic binding pocket. The locations of the amino acids photolabeled by [ 3 H]physostigmine and [ 3 H]galanthamine and the pharmacological specificity of photolabeling establish that physostigmine and galanthamine can bind at the ␣-␥ and ␣-␦ interfaces in the absence and presence of agonist, at the noncanonical ␦-␤ subunit interface, and to a site in the vestibule of the ion channel.
Materials and Methods
Materials. nAChR-rich membranes were isolated from the electric organs of Torpedo californica (5 of either sex; Aquatic Research Consultants) as described previously (Middleton and Cohen, 1991 to Torpedo nAChRrich membranes was determined in the presence of Carb (1 mM), tetracaine (0.1 mM), or proadifen (0.1 mM), respectively.
The concentration-dependent inhibition of radioligand binding was fit using a single site model:
where f(x) is the radioligand binding in the presence of competitor at concentration x, f o is the specific binding in the absence of competitor, f ns is the nonspecific binding, and IC 50 is the concentration of competitor that inhibits the specific binding by 50%.
[ ]galanthamine, in the absence or presence of other drugs, and then irradiated, and the polypeptides were resolved on 8% polyacrylamide/0.33% bis-acrylamide gels as described previously (Blanton and Cohen, 1994; Nirthanan et al., 2005) .
To identify optimal photolabeling conditions, 3 (Savory and Turnbull, 1985) , whereas phototolysis of galanthamine does not produce similar reactive intermediates (Marques et al., 2011) . Consistent with the formation of rubreserine, we found in control experiments with nonradioactive physostigmine in Torpedo physiological saline that irradiation at 312 nm resulted in the formation of a red reaction product with an absorption peak at 500 nm (t 1/2 ϳ5 min). We also found by SDS-PAGE analysis that irradiation of nAChR-rich membranes with 1 M [ 3 H]physostigmine in the presence of nonradioactive physostigmine at concentrations Ͼ0.1 mM, but not in the presence of galanthamine up to 1 mM, resulted in a selective aggregation of rapsyn and a nonspecific reduction in [
3 H]physostigmine photolabeling in nAChR subunits and in non-nAChR polypeptides.
Photolabelings on an analytical scale were carried out in duplicate, with samples resolved in parallel on two acrylamide gels. After staining with Coomassie Blue R-250, the polypeptide bands were excised from one gel for 3 H quantification by liquid scintillation counting (Middleton and Cohen, 1991) , whereas the second gel was prepared for fluorography (Amplify, GE Healthcare) and exposed to Kodak BIOMAX XAR film for 2-4 weeks at Ϫ80°C before excising polypeptide bands for 3 H quantification. For preparative scale photolabelings, the ␤ and ␦ subunits were excised from the stained gel and recovered by passive elution, concentrated to a final volume of 300 l by centrifugal filtration (Vivaspin 15 Mr 5000 concentrators, Sartorius Biotech), and then acetone-precipitated (75% acetone at Ϫ20°C overnight) and resuspended in digestion buffer (15 mM Tris, 0.5 mM EDTA, 0.1% SDS, pH 8.1). The bands containing the nAChR ␣ and ␥ subunits were excised from the stained gel, soaked in overlay buffer (5% sucrose, 125 mM Tris-HCl, 0.1% SDS, pH 6.8) for 30 min, and then transferred to the wells of a 15% acrylamide mapping gel and subjected to in-gel digestion (Blanton and Cohen, 1994) with 100 g of Staphylococcus aureus endoproteinase Glu-C (V8 protease, MP Biochemical). The ␣ and ␥ subunit mapping gels were stained with GelCode Blue (Pierce), and the subunit fragments (␣V8 -20, ␣V8 -18, ␣V8 -10, ␥V8 -14K) (Blanton and Cohen, 1994) were recovered from the gel bands and resuspended in digestion buffer.
Enzymatic fragmentation. Digestions with Lysobacter enzymogenes endoproteinase Lys-C (EndoLys-C) were performed with 1 unit of EndoLys-C (Roche) for 2 weeks or with 1.25 g of EndoLys-C (6.3 unit/ mg, Princeton Separations) for 2 d. For digestion with TPCK-treated trypsin (Worthington Biomedical), samples in digestion buffer were diluted with 0.5% Genapol in 50 mM NH 4 HCO 3 buffer, pH 8.1, to reduce the SDS concentration to Ͻ0.02%; then an equal mass of trypsin was added in CaCl 2 solution (final concentration 0.4 mM) and incubated for 12-48 h. nAChR subunits were digested with 200 g V8 protease for 48 h. All enzymatic digestions were performed at room temperature. EndoLys-C digests of ␦ and ␤ subunits were resolved on small pore (16.5%T, 6%C) Tricine SDS-PAGE gels (Schagger and von Jagow, 1987) , and subunit fragments eluted from selected gel bands were purified by reversed-phase high performance liquid chromatography (rpHPLC). All other digests were fractionated directly by rpHPLC.
rpHPLC purification and sequence analysis. rpHPLC was performed on an HP 1100 binary system using a Brownlee Aquapore BU-300 column. Samples were eluted at 0.2 ml/min using increasing concentrations of 0.05% TFA in acetonitrile or 0.05% TFA in 60% acetonitrile/40% 2-propanol. The elution of peptides and 3 H was monitored by the absorbance at 210 nm and by liquid scintillation counting of a 10% aliquot of each 0.5 ml fraction.
For sequencing on an Applied Biosystems PROCISE 492 protein Sequencer, subunit fragments in digestion buffer and selected rpHPLC fractions were drop-loaded onto Micro TFA filters at 45°C or diluted with 0.1% TFA and loaded onto PVDF filters using Prosorb Sample Preparation Cartridges as described previously . Filters were treated with Biobrene after sample loading. For some sam-ples, sequencing was interrupted at a specific cycle and the filter was treated with o-phthaladehyde (OPA) before resuming sequencing (Middleton and Cohen, 1991) . OPA reacts efficiently with primary amines but not with secondary amines (proline), and treatment with OPA prevents further sequencing of fragments not containing a proline at that cycle (Brauer et al., 1984) . Selected samples were treated with cyanogen bromide to cleave subunit fragments at the C termini of methionines. The samples on sequencing filters were treated in complete darkness with 30 l of 1 M cyanogen bromide in 70% formic acid in water and then wrapped with a layer of Parafilm to prevent evaporation and a layer of aluminum foil to avoid light. After 24 h incubation at room temperature, filters were dried in a Speedvac evaporator and then sequenced. For each cycle of Edman degradation, one-sixth was used for amino acid identification/quantification and five-sixths for 3 H counting. The mass of amino acid detected was quantified from its peak height then fit using SigmaPlot 11 to the equation f(x) ϭ I 0 R x , where I 0 is the initial amount of the peptide sequenced (in pmol), R is the repetitive yield, and f(x) is the pmol detected in cycle x. To simplify figures containing sequencing data, the masses and fit (dotted line) of detected PTH-amino acids are shown for one condition only. The efficiency of amino acid photolabeling in counts per minute per picomole (cpm/pmol) was calculated by (cpm x Ϫ cpm (x Ϫ 1) )/5I o R x .
Molecular modeling and computational analysis.
A model of the extracellular domain of the Torpedo nAChR was constructed from the x-ray structure of the Carb-bound form of the Lymnaea ACh binding protein (Celie et al., 2004 ) (PDB 1UV6) using the Discovery Studio (Accelrys) software package. Physostigmine was docked in the nAChR extracellular domain at the ␣-␥, ␣-␦, and ␦-␤ subunit interfaces in the absence of Carb and also at the ␣-␥ interface in the presence of Carb using CDOCKER (Wu et al., 2003) , a CHARMm-based (Brooks et al., 2009) molecular dynamics simulated-annealing program. For each docking experiment, 30 randomly oriented replicas of physostigmine were seeded at the center of a sphere of radius 25 Å containing all the amino acids at a subunit interface. At the ␣-␥ interface, the sphere was centered at ␥Tyr-111 for docking at the entrance to the transmitter binding site and at ␥Tyr-105 for docking in the vestibule of the ion channel. For each starting seed, CDOCKER was used to generate 10 ligand conformations using high temperature molecular dynamics. The 10 lowest energy orientations were then identified using random rigid-body rotations followed by simulated annealing and a full potential final minimization step. Docking results are shown as Connolly surface representations of the ensemble of the 30 lowest energy docking solutions, with physostigmine shown in stick format in each binding site in the orientation with lowest CDOCKER interaction energy.
Results
In initial experiments, we characterized physostigmine or galanthamine ( 
Photolabeling the nAChR with [
3 H]physostigmine When adult muscle nAChR is exposed to low micromolar concentrations of physostigmine or galanthamine, single-channel responses are observed that appear independent of direct binding to the classic transmitter sites ( When Torpedo nAChR-rich membranes were photolabeled with 1 M [ 3 H]physostigmine and the polypeptides were resolved by SDS-PAGE (Fig. 2) , [ 3 H]physostigmine was photoincorporated in the absence of agonist into each nAChR subunit and into rapsyn, a peripheral protein associating with the cytoplasmic aspect of the nAChR. Inclusion of 1 mM nonradioactive physostigmine, but not Carb or galanthamine, resulted in the selective aggregation of rapsyn and an apparent nonselective reduction of 3 H incorporation in all polypeptides, probably as a result of the formation of rubreserine (see [ 3 H]physostgimine photolabeling, Materials and Methods). Based upon counting of excised gel slices (Fig. 2B) , Carb or ␣-BgTx reduced photoincorporation into the nAChR ␣ subunit by 40% and into the ␥ subunit by 10% and 20%, respectively, whereas photoincorporation was altered by Ͻ5% in the nAChR ␤ subunit or in the Na ϩ /K ϩ -ATPase ␣ subunit (from contaminating membrane fragments). Carb increased and ␣-BgTx decreased photolabeling of the nAChR ␦ subunit by ϳ10%. In the presence of Carb or ␣-BgTx, nonradioactive physostigmine at 100 M decreased [ 3 H]physostigmine photolabeling in the nAChR subunits by 25-40% but by Ͻ5% the Na (Fig. 2B) 3 H]physostigmine-photolabeled ␣ subunit was digested in gel with V8 protease, which produces ␣ subunit fragments with apparent molecular masses of ϳ20 kDa (␣V8 -20), ϳ18 kDa (␣V8 -18), and ϳ10 kDa (␣V8 -10) (Blanton and Cohen, 1994) . Within the primary structure of the ␣ subunit, the ␣V8 -18 fragment begins at ␣Thr-52 and contains the agonist binding site (ABS) segments A (␣Tyr-93) and B (␣Trp-149); the ␣V8 -20 fragment begins at ␣Ser-173 and contains the ABS segment C and the M1-M2-M3 transmembrane helices; and the ␣V8 -10 fragment, which begins at ␣Asn-338, extends to the C terminus and contains the cytoplasmic MA helix and M4 (Unwin, 2005) .
The majority (ϳ80%) of 3 H incorporated in the ␣ subunit was contained in the ␣V8 -20 fragment, with either Carb or ␣-BgTx inhibiting ␣V8 -20 photolabeling by Ͼ75%. Direct sequencing of [ 3 H]physostigmine-photolabeled ␣V8 -20 ( Fig.  3 A, B ) revealed major peaks of 3 H release in cycles 18, 20, and 26 that established photolabeling of 10 , and 20 cpm/pmol, respectively. Photolabeling of those amino acids was inhibited by Ͼ85% in the presence of Carb (Fig. 3A) or ␣-BgTx (Fig. 3B) . Quantification of photolabeling efficiencies indicated that photolabeling of ␣Tyr-190 and ␣Tyr-198 was at least 10 times greater than that of any other aromatic residues within that sequence (Fig. 3C) .
[ 3 H]Physostigmine photoincorporation within ␣V8 -18, which contains ␣Tyr-93 and ␣Trp-149, was at Ͻ20% the level of ␣V8 -20. 3 H incorporation within ␣V8 -18 was recovered in a single peak when an EndoLys-C digest of ␣V8 -18 was fractionated by rpHPLC. Sequence analysis of 3 H peak fractions identified a [
3 H]physostigmine-photolabeled peptide beginning at ␣Ile-78 and a peak of 3 H release at cycle 16 that established photolabeling of ␣Tyr-93 (2 cpm/pmol) that was inhibited by Ͼ90% by Carb (data not shown). Photolabeling of ␣Trp-149 was not determined directly. However, the low level of 3 H incorporation within ␣V8 -18 relative to ␣V8 -20 indicates that photolabeling of ␣Trp-149, if it occurs, will not be higher than the level of photolabeling of ␣Tyr-93, i.e., ϳ10% the efficiency of photolabeling ␣Tyr-198. and 5/6 (ABS Segment E) that are part of a 4-strand antiparallel ␤ sheet forming a rigid surface at the entry to the aromatic binding pocket, and in a stretch of amino acids (ABS Segment F) between ␤ strands 8 and 9 (Celie et al., 2004; Hansen et al., 2005; Unwin, 2005) .
Upon in-gel digestion of [ 3 H]physostigmine-photolabeled ␥ subunit with V8 protease, Ͼ90% of 3 H was recovered in a 14-kDa gel band (␥V8 -14), known to contain the fragment beginning at ␥Val-102 that extends through ABS Segment E (Chiara and Cohen, 1997) . rpHPLC purification of ␥V8 -14 resulted in a single, hydrophilic peak of 3 H. Sequence analysis of this peak confirmed the presence of the fragment beginning at ␥Val-102 and revealed a major peak of 3 H release at cycle 10 of Edman degradation, with smaller peaks in cycles 4 and 16 (Fig. 3D ), establishing that [ 3 H]physostigmine photolabeled ␥Tyr-105 (0.5 cpm/pmol), ␥Tyr-111 (9 cpm/pmol), and ␥Tyr-117 (2 cpm/pmol). Photolabeling of ␥Tyr-111 and ␥Tyr-117 was inhibited by 50 -60% in the presence of Carb (Fig. 3D) or ␣-BgTx (Fig. 3E) , whereas photolabeling of ␥Tyr-105 was enhanced in the presence of Carb but unchanged in the presence of ␣-BgTx (Fig. 3F ) . In the presence of Carb, nonradioactive galanthamine at 300 M inhibited [ 3 H]physostigmine photolabeling of ␥Tyr-105, ␥Tyr-111, and ␥Tyr-117 by ϳ75% (Fig. 3F ) .
We also characterized photolabeling within ␦ subunit fragments beginning at ␦Glu-47, which contains ␦Trp-59, the core aromatic amino acid of ABS Segment D, and ␦Asp-171, containing amino acids of ABS Segment F (␦Ile-178, ␦Asp-180, and ␦Glu-189) (Czajkowski et al., 1993; Prince and Sine, 1996) . The fragment beginning at ␦Glu-47 was isolated from an Endo Lys-C digest of [ 3 H]physostigmine-photolabeled ␦ subunit by Tricine-SDS-PAGE and rpHPLC (Garcia et al., 2007) , whereas the fragment beginning ␦Asp-171 was isolated directly from the digest by rpHPLC.
Sequencing the fragment beginning at ␦Glu-47 (data not shown) revealed photolabeling of ␦Trp-57 (0.8 cpm/pmol); any photolabeling of adjacent aromatic amino acids (␦Trp-64, ␦Tyr-65), if it occurred, was at Ͻ0.2 cpm/pmol. Sequencing the fragment beginning at ␦Asp-171 revealed Carb-independent [ 3 H]physostigmine photolabeling of ␦Tyr-172 (4 cpm/pmol; Fig. 4A ). In contrast, ␣-BgTx reduced photolabeling of ␦Tyr-172 by 70% (Fig. 4B) . We did not attempt to characterize photolabeling in the ␦ subunit ABS Segment E because of the difficulty of achieving the necessary efficient cleavage at ␦Asp-97 (Nirthanan et al., 2005) . ]physostigmine and galanthamine might bind in the nAChR extracellular domain at interfaces not containing ␣ subunits, we characterized photolabeling in an ϳ10-kDa ␦ subunit fragment that begins at ␦Phe-206 and extends through ␤ strand 10 and ␦M1. This fragment was isolated by SDS-PAGE and rpHPLC from EndoLys-C digests of photolabeled ␦ subunit (Garcia et al., 2007) . Sequence analysis of this fragment (Fig. 5) revealed a single peak of 3 H release in cycle 7 that established photolabeling of ␦Tyr-212, which is located in the ␦ subunit primary structure at a position equivalent to ␣Tyr-198 of the ABS Segment C. The efficiency of photolabeling of ␦Tyr-212 was doubled in the presence of Carb (Fig. 5A ) and reduced by ϳ25% in the presence of ␣-BgTx (Fig. 5B) . For nAChRs photolabeled in the presence of Carb, galanthamine inhibited ␦Tyr-212 photolabeling by ϳ50% (Fig. 5C ). The efficiency of photolabeling of ␦Tyr-212 in the presence of Carb (1.5 cpm/pmol) was Ͼ10-fold higher than the photolabeling, if it occurred, of ␦Tyr-218 or ␦Tyr-228, which are contained in the same ␦ subunit fragment, or of ␦Tyr-202, which was characterized by sequencing a longer fragment produced by an alternative cleavage before ␦Asn-200. The efficiency of [ 3 H]physostigmine labeling at ␦Tyr-212 in the absence of agonist was similar to the [ 3 H]physostigmine photolabeling of ␦Tyr-439 within the ␦ subunit cytoplasmic MA helix, the only other photolabeled tyrosine identified within ␦ subunit. However, the efficiency of photolabeling at ␦Tyr-439 (1 cpm/ pmol) was changed by Ͻ20% in the presence of Carb, ␣-BgTx or galanthamine.
Sites and pharmacology of [ 3 H]galanthamine photolabeling mirrors [
3 H]physostigmine photolabeling When nAChRs were photolabeled on an analytical scale with 3 M [ 3 H]galanthamine, photolabeling in the ␣ subunit was inhibited by 80% in the presence of Carb. The other subunits were also photolabeled, but at lower efficiency, with Carb reducing photolabeling in ␥ and ␦ by ϳ25% and in ␤ by Ͻ5%. For nAChRs photolabeled in the presence of Carb, nonradioactive galanthamine at 100 M reduced photolabeling of each nAChR subunit by ϳ25%, whereas photolabeling of the Na ϩ /K ϩ -ATPase ␣ subunit was reduced by Ͻ5%.
For nAChRs photolabeled by [ 3 H]galanthamine in the absence or presence of Carb, amino acid sequence analysis of the ␣ subunit fragment beginning at ␣Ser-173 established [
3 H]galanthamine photolabeling of ␣Tyr-190 and ␣Tyr-198 that was inhibited by Ͼ95% in the presence of Carb (Fig. 6A) . We also characterized [
3 H]galanthamine photolabeling within ABS Segment E of the ␥ subunit by sequence analysis of the fragment beginning at ␥Val-102 (Fig. 6B) (Fig. 6C ) and ␦Tyr-212 in the presence of Carb (Fig. 6D , the only condition examined).
Photolabeling of ␣Lys-125?
An early characterization of photolabeling of Torpedo nAChRrich membranes by 50 M [ 3 H]physostigmine (Schrattenholz et al., 1993) reported the selective photolabeling of one amino acid, ␣Lys-125, which is located in the extracellular domain on ␤ strand 6 projecting into the vestibule of the ion channel at an interface with a ␤ or ␥ subunit. Under our conditions of photolabeling at 1 M [ 3 H]physostigmine, we found that any photolabeling of ␣Lys-125 or the adjacent ␣Tyr-127, if it occurred, was at Ͻ0.2 and 0.05 cpm/pmol, respectively. This was determined by sequence analysis of ␣ subunit fragments beginning at ␣Trp-118/ ␣Thr-119, which were produced by cyanogen bromide cleavage of rpHPLC-purified ␣V8 -18. While we detected photolabeling only of tyrosines and cysteines, it is likely that different photolysis conditions will favor the formation of rubreserine, a chemically reactive o-quinone decomposition product of physostigmine (Savory and Turnbull, 1985) that reacts efficiently with the primary amine of lysine. However, because o-quinones do not react with tyrosines (Pierpoint, 1969) , the photolabeled nAChR tyrosines that we have identified reflect photolabeling by [ 3 H]physostigmine and not by an o-quinone decomposition product.
Discussion
In this work, we use the intrinsic photoreactivities of (Fig. 7) and the pharmacological specificity of photolabeling establish that, in the presence of agonist, each drug binds in the nAChR Table 1 . The arrow and OPA at cycle 2 indicate that sequencing was interrupted and the filter was treated with OPA before resuming sequencing (see Materials and Methods for protein sequencing). extracellular domain at two distinct sites at the canonical ␣-␥ interface (Sites I and II) and to a site at the noncanonical ␦-␤ interface (Site III) in a position equivalent to the benzodiazepine binding site in GABA A receptors (Cromer et al., 2002; Richter et al., 2012) . In addition, in the absence of agonist, each drug binds in the transmitter binding sites (Site IV) in proximity to the core aromatic side chains. The efficiencies of amino acid photolabeling (in cpm/pmol) under the different experimental conditions are summarized in Table 1 . The results of computational docking studies predict other amino acids that contribute to these putative binding sites. (Middleton and Cohen, 1991; Chiara et al., 1998; Nirthanan et al., 2005) and competitive antagonists (Chiara and Cohen, 1997; Chiara et al., 1999 Chiara et al., , 2003 . However, photolabeling by agonists or competitive antagonists at both the principal and complementary surfaces was inhibited completely in the presence of excess agonist (Carb), consistent with mutually exclusive binding. In contrast, whereas [ 3 H]physostigmine or [ 3 H]galanthamine photolabeling of ␣ subunit transmitter binding site core aromatics (␣Tyr-93 and ␣Tyr-190) was inhibited by Ͼ90% in the presence of Carb or ␣-BgTx, photolabeling of amino acids on the ␥ complementary surface (␥Tyr-111/␥Tyr-117) was inhibited by only 50 -60%. These results provide evidence that, in the Carb-bound or ␣-BgTx-bound nAChR, physostigmine or galanthamine can still bind to a site on the complementary surface of the transmitter binding site in proximity to ␥Tyr-111/␥Tyr-117 (Fig. 7B) .
Our computational docking analysis (see Materials and Methods) predicted that, in the presence of Carb, physostigmine binds on the outer surface of the receptor above the entry to the transmitter binding site (Fig. 7C ) in a surface cavity previously identified as a potential drug binding site (Luttmann et al., 2009 ). In its lowest energy orientation, physostigmine is predicted to bind with its pyrolidine PDB#1UV6 (Celie et al., 2004) ). Physostigmine is shown in stick format (magenta, volume, 197 Å 3 ) bound in its lowest energy orientation in four sites, with Connolly surface representations of the ensembles of the 30 lowest energy-docking orientations: in the presence of Carb at the ␣-␥ interface at Site I on the outer surface of the nAChR at the entry to the transmitter binding site (B; expanded in C; volume, 280 Å 3 ) and at Site II in the vestibule of the ion channel (E; expanded in F; volume, 390 Å 3 ), and in the absence of Carb at Site III at the ␦-␤ subunit interface (D, volume, 270 Å 3 ) and at the ␣-␦ interface in the transmitter binding site (Site IV) (A, volume, 250 Å 3 ) . In the absence of Carb, physostigmine is also predicted to bind in the transmitter binding site at the ␣-␥ interface equivalent to Site IV (data not shown). Binding to Site IV is identified by the photolabeling of that is inhibited by Ͼ90% in the presence of Carb or ␣-BgTx. Carb bound at the ␣-␥ transmitter binding site is included in stick format (B, C, E; blue). Amino acids predicted to contribute to each binding site are shown in stick format colored by elements, except in D where ␦Tyr-212 is highlighted in red to contrast with the nonphotolabeled ␦Tyr-202 and ␦Tyr-218 (in blue). The amino acids photolabeled in this study are identified in black by single letter code and subunit position. ␣Lys-125, which was previously reported to be photolabeled by ]galanthamine also photolabeled ␥Tyr-105 (but not ␥Tyr-104), with photolabeling unchanged by ␣-BgTx but increased threefold in the presence of Carb. The selective photolabeling of ␥Tyr-105, but not ␥Tyr-104, is noteworthy because in the nAChR structure both side chains are accessible from the vestibule of the ion channel (Fig. 7E, F) . Because the distance between the ␥Tyr-105 and ␥Tyr-111 side chains (ϳ18 Å) exceeds the length of physostigmine (11 Å), it is unlikely that ␥Tyr-105 and ␥Tyr-111 contribute to a common binding site. Rather, the photolabeling of ␥Tyr-105 provides experimental evidence of a physostigmine and galanthamine binding site in the vestibule of the ion channel in proximity to ␥Tyr-105.
"Blind" computational docking studies using nAChR homology models based upon the structure of AChBP predict two (Luttmann et al., 2009 ) or three (Iorga et al., 2006 physostigmine/galanthamine binding sites in the vestibule of the ion channel. Two sites are predicted at the ␣-␥ interface in proximity to ␥Tyr-105, one extending above and the other below the level of ␥Tyr-105, with the third site lower in the vestibule near ␣Lys-125. When we used computational techniques to dock physostigmine near the ␣-␥ transmitter binding site with bound Carb, a single site was predicted in the vestibule of the ion channel (Fig. 7E, F ) , with the pyrolidine NCH 3 ϩ of physostigmine within 6 Å of ␥Tyr-105 and ␣Asp-89 and the carbamate between ␥Arg-79/␥Pro-81 and ␣Pro-21/␣Val-22 (Fig. 7F ) . Physostigmine access to ␥Tyr-104 is predicted to be blocked by ␥Tyr-105. No fragment containing ␣Tyr-151, the only other tyrosine predicted to contribute to this binding pocket, was identified in this study.
A binding site at the noncanonical ␦-␤ interface Physostigmine and galanthamine also photolabeled ␦Tyr-212, located at the ␦-␤ interface in a position equivalent to ␣Tyr-198 (Fig. 7D) , and that photolabeling was doubled in the presence of Carb. The photolabeling of ␦Tyr-212 in the absence of photolabeling of ␦Tyr-202 or ␦Tyr-218 is significant because in the nAChR structure the latter residues have higher side chain exposure to solvent than does ␦Tyr-212. [
3 H]Physostigmine photolabeling of ␤ subunit residues in proximity to ␦Tyr-212 is not expected because there are no tyrosines on that surface. The selective photolabeling of ␦Tyr-212 provides strong evidence that it contributes to a physostigmine/galanthamine binding pocket. Furthermore, our computational docking predicted a most energetically favored physostigmine binding orientation with the pyrolidine NCH 3 ϩ ϳ5 Å from ␦Tyr-212 and ␤Leu-111 (and the indole NCH 3 ϩ within 4 Å of ␦Tyr-212). This binding pocket is in a position in the nAChR equivalent to the benzodiazepine binding site in GABA A receptors (Cromer et al., 2002; Richter et al., 2012) .
A galanthamine binding site at non-␣-subunit interfaces in heteromeric nAChRs was predicted from studies of mutant AChBPs (Hansen and Taylor, 2007) , and mutational analyses provide evidence for a similar positive allosteric modulator binding site in expressed ␣3␤2 nAChRs for morantel (Seo et al., 2009; Cesa et al., 2012) . The identification of a physostigmine binding site at the ␦-␤ interface raises the possibility of analogous sites at the ␤-␣ or ␥-␣ subunit interfaces. Although there are no tyrosines from the ␣ subunit contributing to those interfaces, further studies are necessary to determine whether [ 3 H]physostigmine photolabels ␤Tyr-204 and/or ␥Tyr-195, which are located at positions equivalent to ␣Tyr-190 and ␣Tyr-198/␦Tyr-212, respectively.
Binding sites for nAChR potentiation or inhibition
Our photolabeling studies identify three distinct nAChR binding sites for physostigmine and galanthamine in the presence of agonist, but further studies over a range of concentrations will be necessary to determine drug binding affinity at each site. Based upon their locations in nAChR structure, each binding site could contribute to the potentiating action of the drugs. For the homomeric ␣7 nAChR, a galanthamine binding site in the presence of agonist on the outer surface of the nAChR below the level of the transmitter binding site was predicted based upon the loss of galanthamine potentiation for the ␣7Thr197Ala mutant nAChR (Ludwig et al., 2010) . In the heteromeric muscle-type nAChR, Torpedo ␣Thr-202 or ␦Thr-216 is equivalent to ␣7Thr-197. ␣Thr-202 is located at the ␣-␥ interface but distant from the photolabeled amino acids in the ␥ subunit (ϳ20Å from ␥Tyr-117 and ϳ30 Å from ␥Tyr-111) and cannot contribute directly to a binding site at the upper entry to the transmitter binding site. We would not expect physostigmine or galanthamine to photolabel Torpedo ␣Thr-202, but because ␣Tyr-203 was not photolabeled (Fig. 3A) , ␣Thr-202 is unlikely to contribute directly to a physostigmine binding site. ␦Thr-216 is located at the ␦-␤ interface in close proximity to the photolabeled ␦Tyr-212. Further studies are required to determine whether, in a muscle-type nAChR, substitutions at ␦Thr-216 affect galanthamine potentiation rather than substitutions at ␣Thr-202.
Mutational analyses established that ␣Asp-89, a position conserved in Cys-loop receptors, plays an important role in nAChR gating by interacting with ␣Thr-150 and affecting the position of ␣Trp-149, a core aromatic of the transmitter binding site (Lee The efficiency of photolabeling of a residue in cycle x of Edman degradation (in cpm/pmol) was calculated from the increased release of 3 H cpm in cycle x and the initial and repetitive yields of released PTH-amino acids. The locations in the nAChR structure of Sites I-IV are identified in Fig. 7. and Sine, 2004; Cashin et al., 2007) . Based upon our results, we predict that physostigmine binding at the site in the vestibule of the ion channel in proximity to ␥Tyr-105 and within 3Å of ␣Asp-89 and ␣Thr-150 (Fig. 7F ) will also perturb agonist gating.
Electrophysiological assays have established that physostigmine and galanthamine have a multiplicity of effects on muscletype nAChRs: (1) direct activation at low efficacy, apparently by acting at a site distinct from the transmitter binding sites; (2) potentiation of ACh responses at submaximal concentrations; and (3) inhibition of ACh responses (Shaw et al., 1985; Akk and Steinbach, 2005; Texidó et al., 2005; Militante et al., 2008) . Although direct binding in the ion channel may account for the inhibition by these drugs, the absence of tyrosines within the lumen of the ion channel makes [
3 H]physostigmine/[ 3 H]galanthamine photolabeling of this site unlikely. In contrast, the broad distribution of tyrosines throughout the extracellular domain of the nAChR has allowed us to directly identify by photoaffinity labeling amino acids contributing to three distinct classes of physostigmine/galanthamine binding sites, and these results provide a starting point for mutational analyses to determine the relative contributions of these different sites to the each drug's ability to directly activate the nAChR or to potentiate or inhibit ACh responses.
